Abstract:1631 Objectives: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra of the brain. Stem cell therapy holds great promise as a potential treatment strategy to produce functional neurons from human pluripotent stem cells (PSCs). A strategy of using PSC-derived dopamine neurons modified to express active or inhibitory forms of DREADD (designer receptors exclusively activated by designer drugs) has been developed to evaluate therapeutic potential for PD treatment in the rhesus monkey model. PET radiotracers of [C-11]clozapine and [C-11]raclopride were used to investigate alterations in binding patterns in the endogenous dopamine competition following treatment with the exogenous designer drug clozapine-N-oxide (CNO). Methods: Five rhesus monkeys underwent a unilateral intracarotid artery injection of MPTP targeting the right substantia nigra or putamen. All monkeys received unilateral intracerebral injections of PSCs with guidance from real-time intraoperative magnetic resonance imaging (RT-IMRI) performed in a 3-T GE SIGNA MRI scanner. Daily doses of CNO were administered to the monkeys to activate the DREADDs expressed by the PSC-derived neurons. Four monkeys underwent [C-11]clozapine scans and one monkey underwent a [C-11]raclopride scan on a microPET Focus 220 scanner. Dynamic data were acquired for 90 minutes post-injection of [C-11]clozapine, and a 120 minute bolus+infusion scan of [C-11]raclopride to assess dopamine release during CNO activation. Regions of interest (ROIs) were drawn for the left putamen, right putamen and cerebellum. Time activity curves (TACs) were generated for each ROI for a semi-quantitative comparison of bilateral differences in putamen uptake following treatment. Results: Asymmetries between the left and right putamen were noticed in the PET data for the [C-11]clozapine scans. Two monkeys showed unilateral uptake of radiotracer with no uptake in the right putamen. The remaining showed bilateral uptake of radiotracer in both the left and right putamen following treatment. The [C-11]raclopride results showed bilateral uptake of radiotracer with elevated uptake in the right putamen following the administration of CNO indicating alteration in dopaminergic function. Conclusions: These qualitative results show the potential for evaluation of PSC-derived neuronal function using PET methodologies. The semi-quantitative analysis will be confirmed through histology studies to show the precise location and effectiveness of PSC engraftment at restoring neuronal function.

The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia

PET‐MRI Applications and Future Prospects in Psychiatry

Progress on the Application of Positron Emission Tomography Imaging of Cannabinoid Type 1 Receptor in Neuropsychiatric Diseases.

Molecular imaging in patients with mood disorders: a review of PET findings

Molecular Imaging in Neuroscience Research with Small-Animal PET in Rodents

PET Brain Imaging in Neurological disorders

Molecular imaging in neuroscience research with small-animal PET in rodents.

The utility of PET imaging in depression

Positron Emission Tomography/Computed Tomography Imaging in Therapeutic Clinical Trials in Alzheimer's Disease: An Overview of the Current State of the Art of Research

International Consensus on Clinical Use of Presynaptic Dopaminergic Positron Emission Tomography Imaging in Parkinsonism.

Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics

The Applications of Positron Emission Tomography in Neurological and Psychiatric Disorders

The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases

The Development, Past Achievements, and Future Directions of Brain PET

Using PET Methods to Evaluate Induced Pluripotent Stem Cell-Derived Neuronal Function

Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson’s Disease

Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective

Neuroimaging biomarkers for drug discovery and development in Schizophrenia

Spatial normalization and quantification approaches of PET imaging for neurological disorders

Positron emission tomography imaging in cardiovascular disease

Novel brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease and mild cognitive impairment